ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

This completed study looked at two diabetes drugs, tirzepatide and sitagliptin, to see which one better prevents heart attacks, strokes, or death in people with type 2 diabetes and heart disease. Researchers analyzed data from over 49,000 patients. The goal was to learn how well …

This study tested a drug called olezarsen in 154 adults with high triglycerides (a type of blood fat) and either heart disease or very high triglycerides. Participants received injections of the drug or a placebo for up to 12 months. The main goal was to see if the drug could low…

This study tested a digital quality improvement program to help doctors better manage LDL (bad) cholesterol in patients with heart disease. Over 1,400 adults with established cardiovascular disease participated. The program used smartphone tools to improve treatment and follow gu…

This phase 2 trial tested olpasiran, an injectable drug, in 281 adults with high lipoprotein(a) – a genetic risk factor for heart disease. Participants received either olpasiran or a placebo. The main goal was to see how much the drug lowered Lp(a) levels after 36 weeks. Results …

This study tested a new drug called AZD0780 in 202 people with heart disease or related risks and high LDL cholesterol. Participants took either the drug or a placebo for 4 weeks, and researchers measured changes in blood pressure using a 24-hour monitor. The goal was to see if A…

This Phase 3 study tested a drug called olezarsen in 1,478 people with very high triglycerides (a type of blood fat) and either heart disease or a high risk for it. Participants received either olezarsen or a placebo as a shot under the skin. The main goal was to see if olezarsen…

This study tested whether a twice-yearly injection (inclisiran) lowers LDL cholesterol better than a daily pill (bempedoic acid) in 402 adults with heart disease who still have high cholesterol despite taking statins. Participants received either inclisiran or bempedoic acid on t…

This early-stage trial tested a new drug called AZD4144 in 29 people who have both heart disease and chronic kidney disease. The main goal was to see if the drug is safe and if it lowers certain markers of inflammation in the blood. The study compared the drug against a placebo o…

This study looked at 3048 adults with heart or blood vessel disease to see if lowering LDL ('bad') cholesterol to a very low level (below 55 mg/dL) is better than the standard target (below 70 mg/dL). Participants received either a statin alone or a statin plus ezetimibe. The goa…

This study tested a new drug called obicetrapib in over 2,500 people with high cholesterol that wasn't well controlled by their current treatments. Participants took either a 10 mg obicetrapib pill or a placebo daily for about 6 months. The main goal was to see if obicetrapib cou…

This study tested whether adding ezetimibe to atorvastatin (a common cholesterol drug) works better than atorvastatin alone in people at very high risk for heart attacks or strokes. Researchers enrolled 137 adults with atherosclerotic cardiovascular disease and measured how much …

This completed study observed over 4,500 adults with atherosclerotic cardiovascular disease who had never had a heart attack or stroke. Researchers compared those taking alirocumab (a cholesterol-lowering drug) to those not on similar therapy, using real-world data to see if the …

This completed study looked at insurance claims data from 70,000 people with type 2 diabetes and established heart disease to compare the heart-related risks of three diabetes drugs: tirzepatide, dulaglutide, and semaglutide. The goal was to see if any of these drugs was linked t…

This study surveyed 608 heart and kidney doctors to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in treating patients with heart disease, kidney disease, or heart f…

This completed study in Egypt examined 1,000 adults with heart disease to see how many reached their LDL cholesterol targets and what got in the way. Participants provided a fasting lipid profile, and researchers looked for patterns and barriers. The goal is to find better ways t…

This study looked at nearly 40,000 people with a history of heart disease caused by clogged arteries. The goal was to measure their levels of lipoprotein(a), a fatty substance that can increase heart risk. Researchers wanted to see how these levels vary by age, sex, race, and reg…

This study used national health survey data to estimate how many US adults with high cholesterol might be eligible for a new drug called inclisiran. Researchers also calculated how many heart attacks and strokes could be prevented over 10 years if these patients took the drug. Th…